Where is SVF obtained from?
SVF can be considered an autologous product obtained from the individual’s own adipose tissue. The preparation of adipose tissue can be performed mechanically or through different laboratory processes. Because the processing method used may affect the product’s cellular composition, regulatory classification, and clinical conditions of use, these methods should not be used interchangeably.
What is found inside SVF?
SVF is not a single “stem cell” population. It may contain different elements such as adipose-derived stromal cells, endothelial and perivascular cells, immune cells, and extracellular matrix components. The resulting cellular profile may vary depending on the preparation method used.
In which areas is SVF being researched?
One of the most intensive clinical research areas is knee osteoarthritis. In addition, there are studies in areas such as soft tissue, wound healing, dermatology, and the scalp; however, the level of evidence and regulatory status of these areas are not the same. Not every research area translates into a routine clinical indication.
Current evidence in knee osteoarthritis
In 2025 and 2026 systematic reviews and randomized trial analyses, positive results in terms of pain and function have been reported with certain SVF and adipose-derived cellular therapies. Conversely, substantial differences exist among the products used, processing methods, cell counts, comparator groups, and patient profiles. Although the results are promising, the need for standardization and long-term data persists.
How is the mode of administration evaluated?
In the musculoskeletal field, SVF or related autologous tissue products can be considered in the form of an injection into the target joint or tissue under the appropriate indication. Prior to administration, the diagnosis must be clarified, the degree of structural damage must be determined, infection and bleeding risks must be evaluated, and the legal/technical nature of the product must be explicitly defined.
Safety
The most frequently reported adverse effects in clinical trials are short-term events such as transient pain, swelling, and tenderness at the procedure site. Nevertheless, the adipose tissue harvesting procedure, injection, and preparation of the cellular product individually carry interventional risks. The need for data regarding long-term safety and the comparability of different products continues.
Why is legislation decisive in Turkey?
The regulatory category under which cellular products obtained from adipose tissue fall may vary depending on the extent to which the product is processed, homologous use status, preparation method, and clinical indication. For this reason, SVF administration should be evaluated not only on clinical grounds, but within the framework of current product and facility authorization conditions.
Our approach at our Bodrum clinic
We do not automatically describe SVF as “stem cells.” We evaluate the source of the product to be administered to the patient, the preparation method, the target tissue, the level of evidence, and the current regulatory status separately. In knee and musculoskeletal system problems, the injection decision is considered together with imaging, biomechanical evaluation, and the rehabilitation plan.
Related pages
- Stem cell treatments
- Mechanical autologous tissue processing and GCell
- Differences between PRP, SVF, and stem cells
Related cellular treatments
Cellular Treatments Main Showcase · PRP Treatment · Differences Between PRP, SVF, and Stem Cells · Application Areas
References
- Han JH, et al. Intra-articular stromal vascular fraction and mesenchymal stromal cell injections in knee osteoarthritis: meta-analysis of randomized trials. Arthroscopy. 2025. PMID: 39914607.
- Recent systematic reviews of adipose-derived cell therapies and SVF for knee osteoarthritis, 2025-2026.
- Safety reviews of autologous SVF therapy, 2024.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: September 14, 2026
Disclaimer: This content is general health information. The use of cellular products is evaluated according to current legislation, product characteristics, center authorization, and indication criteria. In every surgical or interventional procedure, outcomes may vary from person to person. It is recommended that you obtain a detailed opinion from your physician prior to the procedure.
